Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1

BACKGROUND: Gliomas are the most common primary brain tumors. High-Grade Gliomas have a median survival (MS) of 18 months, while Low-Grade Gliomas (LGGs) have an MS of approximately 7.3 years. Seventy-six percent of patients with LGG express mutated isocitrate dehydrogenase (mIDH) enzyme. Survival o...

Descripción completa

Detalles Bibliográficos
Autores principales: Alghamri, Mahmoud S, Thalla, Rohit, Avvari, Ruthvik P, Dabaja, Ali, Taher, Ayman, Zhao, Lili, Ulintz, Peter J, Castro, Maria G, Lowenstein, Pedro R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212865/
https://www.ncbi.nlm.nih.gov/pubmed/32642696
http://dx.doi.org/10.1093/noajnl/vdaa042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212865/
https://www.ncbi.nlm.nih.gov/pubmed/32642696
http://dx.doi.org/10.1093/noajnl/vdaa042

Ejemplares similares